ArticleThe Journal of experimental medicine1997
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction.
Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 94 citations in OpenAlex.
- Cytokine Storm Syndromes Associated with Epstein-Barr Virus.Advances in experimental medicine and biology · 2024Review
- Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues.Frontiers in pharmacology · 2024Review
- IKKα-Mediated Noncanonical NF-κB Signaling Is Required To Support Murine Gammaherpesvirus 68 LatencyJournal of virology · 2022Article
- The interactions between cGAS-STING pathway and pathogens.Signal transduction and targeted therapy · 2020Review
- HSV-1\EGFP stimulates miR-146a expression in a NF-κB-dependent manner in monocytic THP-1 cells.Scientific reports · 2019Article
- Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis.Frontiers in immunology · 2019Review
- Article
- Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.Journal of virology · 2014Article
- Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.Journal of virology · 2014Article
- Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).Molecular immunology · 2013Article
- Roles of cell signaling pathways in cell-to-cell contact-mediated Epstein-Barr virus transmission.Journal of virology · 2012Article
- Article
- NF-κB as a target for oncogenic viruses.Current topics in microbiology and immunology · 2011Review
- Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.Journal of virology · 2010Article
- Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.Journal of virology · 2009Article
- Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program.Journal of virology · 2007Article
- Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.Journal of virology · 2007Article
- Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2.Journal of virology · 2007Article
- Epstein-Barr virus entry.Journal of virology · 2007Review
- Human cytomegalovirus blocks tumor necrosis factor alpha- and interleukin-1beta-mediated NF-kappaB signaling.Journal of virology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Epstein-Barr virus (EBV), an oncogenic human herpesvirus, binds to and infects normal human B lymphocytes via CD21, the CR2 complement receptor. Studies of the mechanisms that enable EBV to infect nonactivated, noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to CD21 on purified resting human B cells rapidly activates the NF-kappaB transcription factor, which, in turn, binds to and mediates transcriptional activation of Wp, the initial viral latent gene promoter. Thus, EBV binding to its cellular receptor on resting B cells triggers an NF-kappaB-dependent intracellular signaling pathway which is required for infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.